Neuraminidase inhibitors

11,590views

Neuraminidase inhibitors

B10

B10

Bacterial structure and functions
Staphylococcus epidermidis
Staphylococcus saprophyticus
Staphylococcus aureus
Streptococcus viridans
Streptococcus pyogenes (Group A Strep)
Streptococcus pneumoniae
Streptococcus agalactiae (Group B Strep)
Enterococcus
Inflammation
Wound healing
Sepsis
Abscesses
Neonatal sepsis
Thymus histology
Spleen histology
Lymph node histology
Introduction to the immune system
Cytokines
Innate immune system
Complement system
T-cell development
B-cell development
MHC class I and MHC class II molecules
T-cell activation
B-cell activation, differentiation, and contraction
Cell-mediated immunity of CD4 cells
Cell-mediated immunity of natural killer and CD8 cells
Antibody classes
Somatic hypermutation and affinity maturation
VDJ rearrangement
Contracting the immune response and peripheral tolerance
B- and T-cell memory
Anergy, exhaustion, and clonal deletion
Vaccinations
Type I hypersensitivity
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
X-linked agammaglobulinemia
Selective immunoglobulin A deficiency
Common variable immunodeficiency
IgG subclass deficiency
Hyperimmunoglobulin E syndrome
Isolated primary immunoglobulin M deficiency
Thymic aplasia
DiGeorge syndrome
Severe combined immunodeficiency
Adenosine deaminase deficiency
Ataxia-telangiectasia
Hyper IgM syndrome
Wiskott-Aldrich syndrome
Leukocyte adhesion deficiency
Chediak-Higashi syndrome
Chronic granulomatous disease
Complement deficiency
Hereditary angioedema
Asplenia
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Glucocorticoids
Introduction to the lymphatic system
Skin histology
Skin anatomy and physiology
Hair, skin and nails
Burns: Clinical
DNA structure
DNA replication
Transcription of DNA
DNA damage and repair
Translation of mRNA
Zika virus
Herpes simplex virus
Herpesvirus medications
Epstein-Barr virus (Infectious mononucleosis)
Influenza virus
Poliovirus
Rubella virus
Parvovirus B19
Rotavirus
Norovirus
Adenovirus
Viral structure and functions
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Gastroenteritis
Bacterial epiglottitis
Helicobacter pylori
Neisseria gonorrhoeae
Varicella zoster virus
Food allergy
Anaphylaxis
Asthma
Immune thrombocytopenia
Autoimmune hemolytic anemia
Hemolytic disease of the newborn
Rheumatic heart disease
Myasthenia gravis
Graves disease
Pemphigus vulgaris
Serum sickness
Systemic lupus erythematosus
Poststreptococcal glomerulonephritis
Graft-versus-host disease
Contact dermatitis
Transplant rejection
Cytomegalovirus infection after transplant (NORD)
Post-transplant lymphoproliferative disorders (NORD)
Thymoma
Ruptured spleen
Mycobacterium tuberculosis (Tuberculosis)
Tuberculosis: Pathology review
Antituberculosis medications
Meningitis, encephalitis and brain abscesses: Clinical
Pneumonia
DNA synthesis inhibitors: Fluoroquinolones
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
Mechanisms of antibiotic resistance
Monoclonal antibodies
Mycoplasma pneumoniae
Pneumonia: Pathology review
Haemophilus influenzae
Legionella pneumophila (Legionnaires disease and Pontiac fever)
Chlamydia pneumoniae
Meningitis
Neisseria meningitidis
Escherichia coli
Salmonella (non-typhoidal)
Salmonella typhi (typhoid fever)
Shigella
Clostridium difficile (Pseudomembranous colitis)
Clostridium botulinum (Botulism)
Azoles
ELISA (Enzyme-linked immunosorbent assay)
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
Blood groups and transfusions
Blood products and transfusion: Clinical
Anti-tumor antibiotics
Sexually transmitted infections: Clinical

Transcript

Watch video only

Neuraminidase inhibitors are antiviral medications mainly used to treat influenza, which is the virus that causes the flu.

There are three types of influenza viruses that infect humans; type A, type B, and type C, and each one has a slightly different genome and set of proteins.

Now, neuraminidase inhibitors work by preventing the release of new viruses from infected cells, thereby limiting the duration of the illness.

Alright, first let’s focus on influenza A and influenza B.

These viruses have two types of glycoproteins on their protective envelope: H protein, or hemagglutinin; and N protein, or neuraminidase.

When the flu virus enters the body, it uses hemagglutinin to bind to sialic acid sugars on the surface of epithelial cells in the upper respiratory tract.

Once bound, the cell swallows up the virus in a process called endocytosis.

Next, the virus releases its viral RNA which moves into the cell’s nucleus.

Now, these RNAs are negative-sense, meaning they need to be transcribed by RNA polymerase into positive-sense mRNA strands.

These strands leave the nucleus and are translated into proteins by ribosomes.

These proteins are then assembled into new viruses.

Now that we have a cell that’s pretty much a virus-producing factory, it will continue to produce more and more viruses which bud off the host cell’s plasma membrane and leave the body.

However, the same hemagglutinin that allowed the virus to attach to the sialic acid sugar on the cell surface, can bind to these sugars again and prevent the viruses from leaving the host cell.

So, in order to be released, the virus uses the neuraminidase proteins to cleave the sialic acid and free itself.

So in short, hemagglutinin allows the virus to enter the cell, while neuraminidase lets the virus leave the cell.

Now, neuraminidase inhibitors, as their name implies, bind and inhibit the enzyme neuraminidase, thereby preventing the release of new viruses.

Common medications in this class include oseltamivir, which is taken perorally as a pill, and zanamivir, which is taken as a powder inhaled by mouth.

Key Takeaways

Neuraminidase inhibitors are antiviral medications used for the treatment and prophylaxis of influenza A and influenza B, which are known to cause the flu. Neuraminidase inhibitors work by blocking an enzyme called neuraminidase produced by the influenza virus. The function of neuraminidase is to help new viruses to get released from infected cells, and so, its inhibition will disrupt further infection of the host's cells. Examples of neuraminidase inhibitors include oseltamivir, and zanamivir.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients" European Respiratory Journal (2015)
  5. "Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013" Antiviral Therapy (2015)
  6. "Clinical use of approved influenza antivirals: therapy and prophylaxis" Influenza and Other Respiratory Viruses (2012)